Matthew Mei, M.D. Assistant t Professor City of Hope Comprehensive Cancer Center

Transcription

1 Treatment of APL Matthew Mei, M.D. Assistant t Professor City of Hope Comprehensive Cancer Center

2 Objectives 1. Urgency of early recognition and treatment 2. Treatment based on risk stratification 3. Monitoring for relapse 4. Treatment of relapse 5. Long-term toxicities

3 Acute Promyelocytic Leukemia Distinguishing g g Features 10-15% of adult AML Leukopenia L k i (85%) Complex coagulopathy t(15;17) chrom translocation Sensitivityy to anthracyclines y PML-RAR fusion transcript Differentiation with retinoic acid Apoptosis with arsenic trioxide

4 Bleeding in APL Oral mucosal bleeding Subcutaneous bleeding Retinal hemorrhages Intracerebral hemorrhage

5 Early Death Rate in APL Population-Based Studies Study N ED Jeddi 41 16% Lehmann 99 31% Alizadeh % McClellan 70 26% Park 1,400 18% Jeddi et al. Hematology, 2008; Lehmann et al. Leukemia, 2010; Alizadeh et al. ASH, 2009; McClellan et al. Haematologica, 2012; Park et al. Blood, 2011

6 Molecular Basis of Leukemogenesis in APL RAR fuses to PML Increased affinity for nuclear co-repressor protein complex (N-coR) Histone deacetylase alters chromatin conformation inhibiting transcription Retinoic i acid (RA) induces release of N-coR permitting transcription RAR RARE msin3 N-CoR HD RA RAR RARE msin3 N-CoR HD PML PML Grignani et al. Nature, 1998

7 Milestones in the Development of Curative Strategies in APL Initial Description, Highly Fatal Daunorubicin ATRA ATRA + Chemo Arsenic Highly Curable ATRA + Arsenic s s 2009 DF FS ECOG Data 0.8 Pre-ATRA era Years Tallman et al. Blood, 2002 OS APL2000 WBC < 10,000/ L WBC 10-50,000/ L WBC > 50,000/ L 0.2 P = Years Kelaidi et al. J Clin Oncol, 2009

8 All-trans Retinoic Acid Natural vitamin A derivative Induces leukemic promyelocytes to differentiate t in vitro Induces CR in almost all pts with APL as single agent No imposition of marrow aplasia At diagnosis Day 12 Day 37

9 Arsenic Trioxide Single most active agent in APL Single-agent tcr rate very high hin frontline and relapsed setting Dual mechanism (differentiation at lower dose, apoptosis at higher dose) Biggest concerns are QTc prolongation and elevated LFTs

10 Molecular Response to Arsenic Trioxide in Relapsed APL: US Multicenter Study with MR ( %) Pa atients 90% % % Baseline Induction Consolidation Maintenance N=29 Soignet et al. J Clin Oncol, 2001

11 Prevention of Early Death in APL ATRA at first suspicion (based on clinical hx and review of peripheral smear), before marrow and before diagnosis is confirmed Frequent platelet transfusions to > 50,000/ L000/ L Cryoprecipitate to maintain fibrinogen > 150 mg/dl No routine heparin No routine antifibrinolytics No leukopheresis Rodeghiero et al. Blood, 1990; Tallman et al. Leukemia Res, 2004; Sanz et al. Blood, 2008

12 Risk Stratification Treatment is primarily based on risk stratification. Risk stratification is easy Initial WBC > 10 = high risk (probably needs some chemotherapy besides just ATRA + ATO) Initial WBC 10 = standard risk (induce with ATRA + ATO)

13 Caveats for Induction in APL Differentiation Syndrome steroid prophylaxis built into the APL 0406 regimen, try to not hold medication if possible. Do NOT do marrow on Day 14 or Day 21! Initial rise in WBC with rising neutrophils represents differentiation of the malignant clone, not true count recovery

14

15 APL 0406 Study Inclusion Criteria Newly diagnosed APL Age years WBC 10 x 10 9 /L WHO performance status 2 Trial designed to assess a non-inferiority margin difference between the group proportions of 5%

16 APL0406 Study: Treatment ATO arm Induction ATO ATR Consolidation ATO ATO ATO ATO 4 weeks on / 4 weeks off 2 weeks on / 2 weeks off Estey et al, Blood 2006 R Induction Consolidation Maintenance Chemo Arm IDA IDA IDA MTZ ATR ATR ATR ATR MTX + 6MP ATR Until CR 3 monthly cycles 2 years Lo Coco et al. NEJM, 2013

17 Induction Outcome ATRA + ATO ATRA + Chemo No. of patients CR, (%) 75 (100%) 75 (95%) Induction death 0 4* Resistant sta t disease 0 0 *Differentiation syndrome (2), ischemic CVA (1) and pneumonia (1) Lo Coco et al. NEJM, 2013

18 APL 0406: Hematologic Toxicity Grade 3-4 thrombocytopenia >15 d p= <.0001 Grade 3-4 neutropenia >15 d p= p= < p= < p=.0185 p= p= < p= < IND I CONS II CONS III CONS IND I CONS II CONS III CONS ATO Chemo Lo Coco et al. NEJM, 2013

19 APL 0406: Other Toxicities Toxicity ATRA+ATO ATRA+Chemo P value QTc prolongation 1,% Hepatic toxicity 1 (Grade 3-4), % Leukocytosis 2 (>10x10 9 /L), % 57 5 < Managed with temporary discontinuation and dose modification of ATO 2. Hydroxyurea 500 mg qid if WBC <50K and 1 g qid if >50K

20 APL 0406 Event-fr ree surviva al probabil lity Event-free Survival ATRA+ATO ATRA+Chemo 97.1% % 85.6% p= Months from diagnosis free surviv val probab bility Disease Disease-free Survival ATRA+ATO ATRA+Chemo Type of event ATRA+ATO ATRA+Chemo Relapse 2 5 Death in CR % p= Months after CR Lo Coco et al. NEJM, 2013

21 APL 0406: Overall Survival rvival pr robabilit ty Ove erall su Lo Coco et al. NEJM, % 91.1% ATRA+ATO ATRA+Chemop= Months from diagnosis

22 APL 0406 Long-term After initial 2013 publication, more patients were enrolled (total n = 276). OS at 50 months was 99.2% vs. 92.6% (p = ) EFS at 50 months was 97.3% vs. 80% (p < 0.003) ATRA + ATO is clear standard of care for newly diagnosed standard risk APL. Grimwade et al. J Clin Oncol, 2009; Grimwade and Tallman Leukemia Res, 2010 Platzbecker U, et al. J Clin Onc 2016.

23 AML17 Randomized phase 3 trial of ATRA + ATO vs. ATRA + chemotherapy for newly diagnosed APL Patients with high risk disease receiving ATRA + ATO only could receive one dose of gemtuzumab ozogamicin 235 patients, 57 high risk Grimwade et al. J Clin Oncol, 2009; Grimwade and Tallman Leukemia Res, 2010 Burnett AK, et al. Lancet Oncol 2015.

24 AML17 ATRA + chemotherapy arm induction / consolidation regimen as per low-risk arm of AIDA2000 ATRA + ATO Induction: ATRA 45 mg/m2 until remission, ATO 0.3 mg/kg D1-5, then twice weekly on weeks 2-8 Consolidation: ATRA 45 mg/m2 D1-14, ATO 03. mg/kg D1-5, twice weekly on weeks 2-4 Gemtuzumab ozogamicin 6 mg/m2 on D1 for high- risk in ATRA + ATO patients Grimwade et al. J Clin Oncol, 2009; Grimwade and Tallman Leukemia Res, 2010 Burnett AK, et al. Lancet Oncol 2015.

25 AML17 results Burnett AK, et al. Lancet Oncol 2015.

26 AML17 Conclusions: Relapse rate lower with ATRA + ATO. Overall survival unchanged in either low-risk or high-risk cohort. Toxicities decreased overall with ATRA + ATO. QOL unchanged. Recent update at ASH 2016 confirmed above findings. Grimwade et al. J Clin Oncol, 2009; Grimwade and Tallman Leukemia Res, 2010 Burnett AK, et al. Lancet Oncol 2015.

27

28 North American Intergroup C9710 Randomized trial for newly diagnosed APL patients. 481 patients enrolled Two randomizations: ATO consolidation (yes/no) Maintenance (ATRA alone vs. ATRA + 6-MP/MTX) Grimwade et al. J Clin Oncol, 2009; Grimwade and Tallman Leukemia Res, 2010 Powell BL, et al. Blood 2010.

29 North American Intergroup C9710 Powell BL, et al. Blood 2010.

30 North American Intergroup C9710 Powell BL, et al. Blood 2010.

31 North American Intergroup C9710 Fairly sizeable advantage realized with addition of ATO consolidation in high and low risk disease for diseasefree and event-free survival. OS not different but p-value (86% vs. 81% at 3 years) Not enough events to evaluate the differential effect of maintenance therapy (p-value for PFS 0.11) Grimwade et al. J Clin Oncol, 2009; Grimwade and Tallman Leukemia Res, 2010 Powell BL, et al. Blood 2010.

32 APML4 Australasian Leukaemia and Lymphoma Group Single-arm phase 2 trial with 124 patients, median followup for 2 years. Both low and high-risk patients were included. Grimwade et al. J Clin Oncol, 2009; Grimwade and Tallman Leukemia Res, 2010 Iland H, et al. Blood 2012.

33 APML4 INDUCTION CONSOLIDATION (1) MAIN ATRA D 1-35 ATRA D 1-28 ATRA, 6-MP IDA D 2,4,6,8 ATO D 1-28 MTX ATO D 9-36 PRED D 1-10 CONSOLIDATION (2) ATRA D 1-7, 15-21, ATO D 1-5, 8-12, 22-26, Iland H et. al, Blood 2012

34 eapse-fre % alive and % relapse free Low Inter High APML4 DFS by Sanz Risk Category 100% ee100-low Low Intermediate 20- High P [ trend ] = P value (trend) = year relapse free rate: 100%, 97%, 95%, 5 year: 100%, 93%, 95% Years from documented HCR Number at risk Years 57 from 46 documented HCR High 95% Intermediate 93%

35 APML update (5-year data): 5-yr OS 94% overall (high-risk h i 87%) 5-yr DFS 95% 5-yr EFS 90% 3 patients relapsed between the interim 2-year analysis and the 5-year update. Iland H et. al, Lancet Oncol Grimwade et al. J Clin Oncol, 2009; Grimwade and Tallman Leukemia Res, 2010

36 High-Risk APL ATRA + Risk-Adapted Chemo vs APML4 Number Median follow up IDA equivalent (months) (mg/m 2 ) (g/m 2 ) AraC DFS CIR OS PETHEMA LPA % 14% 79% European APL % 88% GIMEMA AIDA % 9% 83% ALLG APML % 5% 87% Sanz et al. Blood, 2010; Adès et al. Am J Hematol, 2013; Lo Coco et al. Blood, 2010; Sanz et al. Best Pract Res Clin Haematol, 2003; Iland et al. ASH, 2014

37 MRD Monitoring Document molecular CR from marrow after consolidation (slightly more sensitive than PB by 1.5 logs) Unclear benefit in low-risk disease Potential benefit in high-risk disease, never prospectively validated, but treatment of molecular relapse is easier than hematologic relapse Monitor from PB q3 mo. for 2 yrs for high-risk, age >60, therapy interruptions or intolerance Low-risk: may not be necessary If pos PCR, repeat in 2-4 weeks; if persistent t positive, treat t as relapse Grimwade et al. J Clin Oncol, 2009; Grimwade and Tallman Leukemia Res, 2010; Grimwade Best Pract Res Clin Haematol 2015

38

39 Relapsed APL Molecular relapse ATO x 2 cycles Autograft in CR2 Morphologic relapse ATO x 2 cycles: CR 85% Autograft in CR2: 5-yr DFS 70-80% Isolated CNS relapse ATO crosses into CNS 30-50% serum levelsl ATO x 2 cycles, IT MTX/ara-C, autograft L C Bl d 1999 d 2004 E t L k i 2007 E t Bl d 2002 M l i Bl d 1997 d B tt Lo Coco Blood, 1999 and 2004; Esteve Leukemia, 2007, Estey Blood, 2002; Meloni Blood,1997; de Botton J Clin Oncol, 2005; Thomas Haematologica, 2006; Kohno Int J Hem, 2008, Kharfan-Dabaja BBMT, 2007; Au J Clin Oncol 2000; Knipp Leuk Res, 2007; Sanz Blood, 2009

40 Adjusted Probability of Overall Survival APL in CR Probabil lity allohsct autohsct Months Chakrabarty et al. BBMT, 2014

41 Late Toxicities 3-5% death rate in CR reported in PETHEMA and European APL trials 1,2 Heart failure, secondary malignancies, especially as historical APL regimens have included a lot of anthracycline Possible late toxicities with ATO hypertension, DM, arrhythmia 3 1 Sanz MA, et al. Blood Ades L, et al. Blood Shetty AV, et al. ASH 2014.

42 ASH 2016 Updates Two trials for high risk patients: 1) APL2006 Induction with ATRA + ida 12mg/m2 x 3 days + ara-c 200 mg/m2 x 7 days (7+3) Randomization between consolidation chemotherapy with or without ATO, ara-c later removed from ATO arm due to toxicity, results ultimately comparable 2) SWOG/Alliance/ECOG S0535 Untreated high-risk patients, GO 9 mg/m2 on D1, ATRA + ATO until remission. i Consolidation ATO x 2, ATRA + dauno x 2, GO x 2, maintenance ATRA + 6MP/MTX 3y EFS 79% Lu et al. Blood, 2002; Kumana et al. Eur J Clin Pharmacol, 2002; Au et al. Leukemia Res, 2007; Au et al. Blood 2006 and 2008

43

44 Provocative Thoughts Regarding Treatment of APL ONY AML WHERE Current therapy is directed at less chemo and can be cured with NO chemo Current strategies focus early (ED) and late (maintenance) phases of treatment Disease is as sensitive among older adults as younger Risk stratification is very simple Treatment of relapsed disease is highly effective Autograft is treatment of choice in CR2 not allograft